Selected Antimicrobial Information – Companion Animal
Ceftazidime [Companion]
Restriction Status
Selectively Use
Dose
| Species | Usage | Dose |
|---|---|---|
| Cats |
Treatment of Pseudomonas aeruginosa or Gram-negative aerobic infections not susceptible to other antibiotics | 30mg/kg IV q6h (reduce frequency of administration to q8h in patients with renal insufficiency) (extra-label use) |
| For CRI | 3-4mg/kg IV loading dose, then 3-4mg/kg/hr IV CRI (extra-label use) | |
| Dogs |
For orthopedic infections | 30mg/kg IV q6h (reduce frequency of administration to q8h in patients with renal insufficiency) (extra-label use) |
| For soft tissue infections | 30mg/kg IV q6h (reduce frequency of administration to q8h in patients with renal insufficiency) (extra-label use) | |
| For sepsis | 30mg/kg IV q4-8h (extra-label use) | |
| For CRI | 3-4mg/kg IV loading dose, then 3-4mg/kg/hr IV CRI (extra-label use) |
Brand Name(s)
Ceptaz®, Fortaz®, Tazicef
Background
Ceftazidime is a bactericidal, time-dependent third generation cephalosporin (β-lactam) antibiotic with excellent activity against Gram-negative bacteria such as Enterobacteriaceae and Pseudomonas aeruginosa. There is some activity against anaerobes. It is not effective against Enterococcus spp. or methicillin-resistant Staphylococcus spp. Distribution throughout the body is wide, and ceftazidime reaches therapeutic concentrations in both bone and CSF. Elimination is primarily as unchanged drug in urine.
Acceptable Uses
- Treatment of Pseudomonas aeruginosa or Gram-negative aerobic infections not susceptible to other antibiotics, including sepsis, meningitis, osteomyelitis, or pneumonia. Sometimes used in combination with an aminoglycoside or clindamycin when antimicrobial resistance is anticipated.
Unacceptable Uses
- N/A
Formulations Available within the OSU Pharmacy
- Ceftazidime 2g/10ml injectable suspension
Notes
- This should be used selectively (i.e. as a second resource drug).
- It is recommended that this medication be used only via IV administration due to pain and injection site reactions with SQ or IM administration.
